Información del artículo
Resumen
Con la depleción estrogénica se produce un aumento del remodelado óseo, cuyo grado podemos determinar mediante el análisis de los marcadores bioquímicos de remodelado óseo. En los últimos años se ha puesto mucho énfasis en establecer la relación entre estas tasas de remodelado óseo, determinadas a partir de los valores en los marcadores, con la pérdida ósea y la posibilidad de fractura y como indicadores reales del beneficio de la terapia antirresortiva. Como comentaremos a continuación, aunque existen varios estudios que demuestran su capacidad predictora de pérdida ósea y de posibilidad de fractura, el uso más establecido en la actualidad es el de monitorizar el tratamiento y establecer la adhesión (compliance) de la paciente a la terapia
Palabras clave:
Posmenopausia
Terapia antirresortiva
Predicción de pérdida ósea y de fractura
Beneficio del tratamiento
Summary
With estrogenic depletion, bone remodeling increases. The degree of this remodeling can be determined by analysis of biochemical markers of bone turnover. In the last few years, great efforts have been made to establish the relationship between rates of bone remodeling, determined by levels of markers, and bone loss and the possibility of fracture, as well as to establish the role of these markers as faithful indicators of the benefits of antiresorptive therapy. As will be seen, although several studies demonstrate the capacity of these markers to predict bone loss and the possibility of fracture, currently they are more frequently used to monitor therapy and establish patients' compliance with treatment
Keywords:
Postmenopause
Antiresorptive therapy
Prediction of bone loss and fracture
Treatment benefit
El Texto completo está disponible en PDF
Bibliografía
[1.]
B.L. Riggs, S. Khosla, L.J. III. Melton.
A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men.
J Bone Miner Res, 13 (1998), pp. 763-773
[2.]
B.L. Riggs, L.J. Melton.
III. Involutional osteoporosis.
N Engl J Med, 314 (1986), pp. 1676-1686
[3.]
H.G. Ahlborg, O. Johnell, B.E. Nilsson, S. Jeppsson, G. Rannevik, M.K. Karlsson.
Bone loss in relation to menopause: a prospective study during 16 years.
Bone, 28 (2001), pp. 327-331
[4.]
P.R. Ebeling, L.M. Atley, J.R. Guthrie, H.G. Burger, L. Dennerstein, J.L. Hopper, et al.
Bone turnover markers and bone density across the menopausal transition.
J Clin Endocrinol Metab, 81 (1996), pp. 3366-3371
[5.]
P. Garnero, P.D. Delmas.
Biochemical markers of bone turnover: clinical usefulness in osteoporosis.
Ann Biol Clin (Paris), 57 (1999), pp. 137-148
[6.]
H. Hoshino, K. Kushida, M. Takahashi, K. Yamazaki, M. Denda, K. Atsumi, et al.
Changes in levels of biochemical markers and ultrasound indices of Os calcis across the menopausal transition.
Osteoporos Int, 11 (2000), pp. 128-133
[7.]
P. Garnero, E. Sornay-Rendu, M.C. Chapuy, P.D. Delmas.
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
J Bone Miner Res, 11 (1996), pp. 337-349
[8.]
P. Garnero, E. Gineyts, P. Arbault, C. Christiansen, P.D. Delmas.
Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
J Bone Miner Res, 10 (1995), pp. 641-649
[9.]
P. Garnero, E. Sornay-Rendu, F. Duboeuf, P.D. Delmas.
Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study.
J Bone Miner Res, 14 (1999), pp. 1614-1621
[10.]
D.C. Bauer, P.M. Sklarin, K.L. Stone, D.M. Black, M.C. Nevitt, K.E. Ensrud, et al.
Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures.
J Bone Miner Res, 14 (1999), pp. 1404-1410
[11.]
M.A. Hansen, K. Overgaard, B.J. Riis, C. Christiansen.
Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study.
Bmj, 303 (1991), pp. 961-964
[12.]
A. Rogers, R.A. Hannon, R. Eastell.
Biochemical markers as predictors of rates of bone loss after menopause.
J Bone Miner Res, 15 (2000), pp. 1398-1404
[13.]
H.N. Rosen, A.C. Moses, J. Garber, D.S. Ross, S.L. Lee, S.L. Greenspan.
Utility of biochemical markers of bone turnover in the follow- up of patients treated with bisphosphonates.
Calcif Tissue Int, 63 (1998), pp. 363-368
[14.]
N. Yoshimura, T. Hashimoto, K. Sakata, S. Morioka, T. Kasamatsu, C. Cooper.
Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck: the Taiji study.
Calcif Tissue Int, 65 (1999), pp. 198-202
[15.]
J.Y. Reginster, R. Deroisy, J. Collette, A. Albert, B. Zegels.
Prediction of bone loss rate in healthy postmenopausal women.
Calcif Tissue Int, 60 (1997), pp. 261-264
[16.]
P. Garnero, E. Sornay-Rendu, F. Duboeuf, P.D. Delmas.
Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study.
J Bone Miner Res, 14 (1999), pp. 1614-1621
[17.]
P. Ravn, M. Rix, H. Andreassen, B. Clemmesen, M. Bidstrup, M. Gunnes.
High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women.
Calcif Tissue Int, 60 (1997), pp. 255-260
[18.]
P. Ravn, C. Fledelius, C. Rosenquist, K. Overgaard, C. Christiansen.
High bone turnover is associated with low bone mass in both pre- and postmenopausal women.
Bone, 19 (1996), pp. 291-298
[19.]
J.S. Johansen, B.J. Riis, P.D. Delmas, C. Christiansen.
Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women.
Eur J Clin Invest, 18 (1988), pp. 191-195
[20.]
K. Akesson, P. Vergnaud, E. Gineyts, P.D. Delmas, K.J. Obrant.
Impairment of bone turnover in elderly women with hip fracture.
Calcif Tissue Int, 53 (1993), pp. 162-169
[21.]
M. Hedstrom, K. Sjoberg, J. Svensson, E. Brosjo, N. Dalen.
Changes in biochemical markers of bone metabolism and BMD during the first year after a hip fracture.
Acta Orthop Scand, 72 (2001), pp. 248-251
[22.]
L.J. III Melton, E.J. Atkinson, M.K. O'Connor, W.M. O'Fallon, B.L. Riggs.
Bone density and fracture risk in men.
J Bone Miner Res, 13 (1998), pp. 1915-1923
[23.]
R.D. Chapurlat, P. Garnero, G. Breart, P.J. Meunier, P.D. Delmas.
Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study.
Bone, 27 (2000), pp. 283-286
[24.]
P. Garnero, E. Hausherr, M.C. Chapuy, C. Marcelli, H. Grandjean, C. Muller, et al.
Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
J Bone Miner Res, 11 (1996), pp. 1531-1538
[25.]
B.J. Riis, M.A. Hansen, A.M. Jensen, K. Overgaard, C. Christiansen.
Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study.
Bone, 19 (1996), pp. 9-12
[26.]
A.M. Tromp, M.E. Ooms, C. Popp-Snijders, J.C. Roos, P. Lips.
Predictors of fractures in elderly women.
Osteoporos Int, 11 (2000), pp. 134-140
[27.]
B.J. Riis, M.A. Hansen, A.M. Jensen, K. Overgaard, C. Christiansen.
Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study.
Bone, 19 (1996), pp. 9-12
[28.]
E. Gineyts, P.A. Cloos, O. Borel, L. Grimaud, P.D. Delmas, P. Garnero.
Racemization and isomerization of type I collagen C-te-lopeptides in human bone and soft tissues: assessment of tissue turnover.
Biochem J, 345 (2000), pp. 481-485
[29.]
P. Garnero, F. Bianchi, M.C. Carlier, V. Genty, N. Jacob, S. Kamel, et al.
Biochemical markers of bone remodeling: pre-analytical variations and guidelines for their use.
Ann Biol Clin (Paris), 58 (2000), pp. 683-704
[30.]
P. Garnero, E. Sornay-Rendu, B. Claustrat, P.D. Delmas.
Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.
J Bone Miner Res, 15 (2000), pp. 1526-1536
[31.]
P. Vergnaud, P. Garnero, P.J. Meunier, G. Breart, K. Kamihagi, P.D. Delmas.
Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study.
J Clin Endocrinol Metab, 82 (1997), pp. 719-724
[32.]
P.L. van Daele, M.J. Seibel, H. Burger, A. Hofman, D.E. Grobbee, J.P. van Leeuwen, et al.
Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study.
Bmj, 312 (1996), pp. 482-483
[33.]
H.G. Bone, J.r. Downs RW, J.R. Tucci, S.T. Harris, R.S. Weinstein, A.A. Licata, et al.
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
J Clin Endocrinol Metab, 82 (1997), pp. 265-274
[34.]
A.M. Parfitt.
Bone age, mineral density, and fatigue damage.
Calcif Tissue Int, 53 (1993), pp. 82-85
[35.]
S.L. Greenspan, R.A. Parker, L. Ferguson, H.N. Rosen, L. Maitland- Ramsey, D.B. Karpf.
Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
J Bone Miner Res, 13 (1998), pp. 1431-1438
[36.]
P. Garnero, W.J. Shih, E. Gineyts, D.B. Karpf, P.D. Delmas.
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
J Clin Endocrinol Metab, 79 (1994), pp. 1693-1700
[37.]
C.J. Rosen, C.H. III. Chesnut, N.J. Mallinak.
The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
J Clin Endocrinol Metab, 82 (1997), pp. 1904-1910
[38.]
R.P. Hesley, K.A. Shepard, D.K. Jenkins, B.L. Riggs.
Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline.
Osteoporos Int, 8 (1998), pp. 159-164
[39.]
P. Ravn, J.O. Christensen, M. Baumann, B. Clemmesen.
Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment.
Bone, 22 (1998), pp. 559-564
[40.]
R. Hannon, A. Blumsohn, K. Naylor, R. Eastell.
Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.
J Bone Miner Res, 13 (1998), pp. 1124-1133
[41.]
I.I.I. Chesnut CH, N.H. Bell, G.S. Clark, B.L. Drinkwater, S.C. English, J.r. Johnson CC, et al.
Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density.
Am J Med, 102 (1997), pp. 29-37
[42.]
C. Cooper, J.A. Stakkestad, S. Radowicki, P. Hardy, C. Pilate, M.P. Dain, et al.
Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.
Osteoporos Int, 9 (1999), pp. 358-366
[43.]
P.D. Delmas, P. Hardy, P. Garnero, M. Dain.
Monitoring individual response to hormone replacement therapy with bone markers.
Bone, 26 (2000), pp. 553-560
[44.]
B.J. Riis, K. Overgaard, C. Christiansen.
Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy.
Osteoporos Int, 5 (1995), pp. 276-280
[45.]
E. Fink, C. Cormier, P. Steinmetz, C. Kindermans, Y. Le Bouc, J.C. Souberbielle.
Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
Osteoporos Int, 11 (2000), pp. 295-303
[46.]
P.J. Meunier, E. Confavreux, I. Tupinon, C. Hardouin, P.D. Delmas, R. Balena.
Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up).
J Clin Endocrinol Metab, 82 (1997), pp. 2784-2791
[47.]
D. Thiebaud, P. Burckhardt, H. Kriegbaum, H. Huss, H. Mulder, J.R. Juttmann, et al.
Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
Am J Med, 103 (1997), pp. 298-307
[48.]
P.D. Delmas, N.H. Bjarnason, B.H. Mitlak, A.C. Ravoux, A.S. Shah, W.J. Huster, et al.
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
N Engl J Med, 337 (1997), pp. 1641-1647
[49.]
G. Thamsborg, J.E. Jensen, G. Kollerup, E.M. Hauge, F. Melsen, O.H. Sorensen.
Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
Bone, 18 (1996), pp. 207-212
[50.]
R. Marcus, L. Holloway, B. Wells, G. Greendale, M.K. James, C. Wasilauskas, et al.
The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
J Bone Miner Res, 14 (1999), pp. 1583-1595
[51.]
L. Alvarez, N. Guanabens, P. Peris, S. Vidal, I. Ros, A. Monegal, et al.
Usefulness of biochemical markers of bone turnover in assessing response to the treatment of paget's disease.
Bone, 29 (2001), pp. 447-452
Copyright © 2002. Sociedad Española de Ginecología y Obstetricia